Indication: Prostate Cancer

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castrate-Resistant

Sub-indication: Metastatic Castrate-Resistant Prostate Cancer- Patients must have been previously treated with at least 1, but no more than 2 previous taxane regimens.

Line of Therapy: 2nd Line

Drug Study

Principal Investigator: Arash Rezazadeh, M.D.
Norton Cancer Institute

Sponsor: Endocyte, Inc.

Learn more at ClinicalTrials.gov

Email for more information: GU-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.